Prescribing, Policies and Pathways
or
Medicine / Guideline | Indication | RAG rating | Document type | Place |
---|---|---|---|---|
Alirocumab | Primary hypercholesterolaemia and mixed dyslipidaemia | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Aliskiren | Hypertension | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Alteplase | Acute ischaemic stroke | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Ambrisentan | Pulmonary arterial hypertension (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Amiodarone Shared Care Protcol | Arrythmia | Amber protocol | Shared care protocol | Hertfordshire and West Essex ICB |
Anagrelide | Reduction of elevated platelet counts | Red | n/a | Hertfordshire and West Essex ICB |
Andexanet alfa | Reversal of anticoagulation | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Apixaban (generic 1st line) | Atrial fibrillation | Green | n/a | Hertfordshire and West Essex ICB |
Apixaban (generic 1st line) | Treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE) and prevention of recurrent DVT and PE | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Apixaban (generic 1st line) | VTE prophylaxis following hip and knee surgery | Red | n/a | Hertfordshire and West Essex ICB |
Atrial Fibrillation (AF) | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
Bempedoic acid | Primary hypercholesterolaemia or mixed dyslipidaemia | Green | NICE technology appraisal | Hertfordshire and West Essex ICB |
Bosentan | Digital ulcers and pulmonary arterial hypertension (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Cangrelor | Reduction of atherothrombotic events in PCI | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Cilostazol | Intermittent claudication in people with peripheral arterial disease | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Ciprofibrate | Hypercholesterolaemia | Double Red | n/a | Hertfordshire and West Essex ICB |
Colesevelam | Bile acid sequestrants for prevention of CVD | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Colestyramine | Bile acid sequestrants for prevention of CVD | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Dalteparin | Anticoagulation | Red | n/a | Hertfordshire and West Essex ICB |
Dapagliflozin | Chronic Heart Failure | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Diagnosing Asymptomatic Heart Murmur | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
DOACs | Anticoagulation - Atrial fibrillation (AF) guidance | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
DOACs | Anticoagulation - interactions | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
DOACs | Anticoagulation - counselling checklist | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Doxazosin (prolonged release) | Hypertension, benign prostatic hyperplasia (BPH) | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Dronedarone - Adults | Arrythmia | Amber protocol | Shared care protocol | Hertfordshire and West Essex ICB |
Empagliflozin | Chronic Heart Failure | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Enoxaparin | Anticoagulation | Red | n/a | Hertfordshire and West Essex ICB |
Evolocumab | Primary hypercholesterolaemia and mixed dyslipidaemia | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Exercise Protocol for the Management of CHD (Exercise for Cardiac Conditions) | n/a | Clinical pathways | East and North Hertfordshire | |
Gemfibrozil | Hypercholesterolaemia | Double Red | n/a | Hertfordshire and West Essex ICB |
Heart Failure Suspected | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
Heart failure with reduced ejection fraction (HFrEF) in primary care (Confirmed) | Follow up pathway | Red | Clinical pathways | Hertfordshire and West Essex ICB | |
Hypertension guidelines in adults | Hypertension | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Hypertension in Adults - Diagnosis and Initial Management | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
Icosapent ethyl | Hypertriglyceridemia | Red | Decision document | Hertfordshire and West Essex ICB |
Inclisiran | Primary hypercholesterolaemia and mixed dyslipidaemia | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
Inclisiran | Primary hypercholesterolaemia and mixed dyslipidaemia | Amber initiation | Prescribing support document | Hertfordshire and West Essex ICB |
Inositol nicotinate | Intermittent claudication in people with peripheral arterial disease | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Ivabradine | stable angina and chronic heart failure | Amber initiation | Prescribing support document | Hertfordshire and West Essex ICB |
Left Ventricular Systolic Dysfunction (LVSD) Management | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
Lipid management | patient decision aid statin therapy | n/a | Patient information | Hertfordshire and West Essex ICB |
Lipid management pathway | Statin intolerance | n/a | Prescribing pathway | Hertfordshire and West Essex ICB |
Lipid management pathway | Primary & secondary prevention | n/a | Prescribing pathway | Hertfordshire and West Essex ICB |
Lomitapide | Homozygous familial hypercholesterolaemia (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Low molecular weight heparin (LMWH) | Anticoagulation | Red | Decision document | Hertfordshire and West Essex ICB |
Macitentan | Pulmonary arterial hypertension (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Metolazone | Oedema | n/a | Patient information | Hertfordshire and West Essex ICB |
Metolazone | Oedema | Red | Decision document | Hertfordshire and West Essex ICB |
Mexiletine | Life threatening ventricular arrhythmias (unlicensed - acute provider only) | Red | n/a | Hertfordshire and West Essex ICB |
Naftidrofuryl Oxalate | Intermittent claudication in people with peripheral arterial disease | Green | NICE technology appraisal | Hertfordshire and West Essex ICB |
Nicotinic acid | Prevention of CVD | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Omega 3 fatty acid | Primary or secondary prevention of CVD, sleep problems, multiple sclerosis (MS), familial hypercholesterolemia | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Omega 3 fatty acid | Hypertriglyceridaemia - severe | Amber initiation | Decision document | Hertfordshire and West Essex ICB |
Omega-3 Fatty Acids Patient Information Leaflet | Primary or secondary prevention of CVD, sleep problems, multiple sclerosis (MS), familial hypercholesterolemia | n/a | Patient information | Hertfordshire and West Essex ICB |
Palpitations | n/a | Clinical pathways | East and North Hertfordshire | |
Pentoxifylline | Intermittent claudication in people with peripheral arterial disease | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Perindopril arginine | Heart failure, hypertension and prophylaxis of CV events | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Perindopril Arginine Patient information leaflet | Heart failure, hypertension and prophylaxis of CV events | n/a | Patient information | Hertfordshire and West Essex ICB |
Prasugrel | Percutaneous coronary intervention (PCI) for treating acute coronary syndromes (ACS) | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
Rivaroxaban | Prevention of atherothrombotic events in patients after an acute coronary syndrome | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
Rivaroxaban | Preventing atherothrombotic events in people with coronary or peripheral artery disease | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Sacubitril valsartan | Heart failure | Amber initiation | Prescribing support document | Hertfordshire and West Essex ICB |
Sildenafil (20mg tablets) | Pulmonary arterial hypertension (NHSE) | Red | n/a | Hertfordshire and West Essex ICB |
Statin patient decision aid - NICE | Hypercholesterolaemia | n/a | Patient information | Hertfordshire and West Essex ICB |
Tenecteplase | Acute ischaemic stroke | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Ticagrelor | Preventing atherothrombotic events after myocardial infarction | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
Ticagrelor | Treatment of acute coronary syndromes | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
Varicose Veins Management | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
Vericiguat | Heart failure - chronic with reduced ejection fraction | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Vernakalant | Atrial fibrillation | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |